What is the latest update in the longevity market?

Download our beautiful pitch about the longevity market

Summary table of the most important updates in the longevity market

We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.

We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.

We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.

You can also get all the latest market news for the month here.

News	Category	Date	Source
The U.S. government formally funded seven healthspan research teams through ARPA-H's PROSPR program	Strategic Investments	February 24, 2026	ARPA-H
Corsera Health raised $80 million in a Series A and began dosing its first clinical trial	Fundraising	January 7, 2026	Business Wire
Mubadala invested $36.5 million in L-Nutra, bringing its Series D to $83.5 million	Fundraising	January 21, 2026	PR Newswire
20/20 BioLabs launched OneTest for Longevity, an AI-powered blood test built with IBM	Product Launch	February 25, 2026	Financial Content
UFC GYM and NexGen MD Scientific partnered to bring longevity clinics into gyms	Partnership	February 25, 2026	PR Newswire
Human Longevity launched a personal AI-powered longevity app for its members	Product Launch	February 18, 2026	PR Newswire
Human Longevity and the LEV Foundation teamed up to study centenarians and find longevity biomarkers	Partnership	March 25, 2026	PR Newswire
Agentis Longevity acquired BioDesign to expand its longevity clinic footprint in Florida	M&A	February 5, 2026	PR Newswire
January AI launched an enterprise AI platform for longevity and health companies at CES 2026	New Tech	January 7, 2026	Fitt Insider
The Healthspan Action Coalition reached 300 member organizations, becoming the world's largest healthspan alliance	Partnership	January 21, 2026	Healthspan Action
Withings launched Body Scan 2, a home longevity station tracking over 60 biomarkers	Product Launch	January 5, 2026	Withings
Immorta Bio reported doubling mouse lifespan using a senolytic and stem cell combination therapy	Breakthrough	January 8, 2026	PR Newswire

How is the longevity market doing now?

How do we define the longevity market?

We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.

We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.

We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.

This is also the definition we use in our report covering the longevity market.

How big is the longevity market in 2026?

Our best estimate is that the longevity market is worth somewhere between $27 billion and $32 billion in 2026, with $29 billion as the most likely figure.

This is not a random guess, if you want to know how we have come up with this estimate, you can read our longevity market size analysis here.

To put that in perspective, the longevity market is larger than the global smart ring market (around $1 billion) but smaller than the probiotics market (around $60 billion) and sits well below the broader dietary supplements market (around $180 billion).

The longevity market is still early and fragmented, with more than 3,200 startups globally and no single company holding more than 5% market share, which means there is still a lot of room for consolidation and category leaders to emerge.

How fast will the longevity market grow in the future?

A realistic growth rate for the longevity market is around 8% per year, which balances strong consumer demand with the fact that most longevity drugs are still years away from regulatory approval.

At 8% annual growth, the longevity market should reach around $43 billion by 2030 and approximately $68 billion by 2036.

That growth pace is similar to the broader health and wellness sector, faster than traditional pharmaceuticals, and slower than pure digital health, which makes the longevity market a steady rather than explosive growth story for now.

What does current funding activity look like in the longevity market?

Our team, who continually updates our longevity market pitch deck, is keeping a close eye on the market and tracking key signals.

One of those signals is fundraising activity across startups. Each month, we refresh this page with a list of startups in the longevity market that have raised funding, and we also publish a quarterly analysis here.

Is funding momentum accelerating or cooling in the longevity market these days?

In Q1 2026, the longevity market saw its two largest disclosed rounds come in at $80 million (Corsera Health) and $83.5 million total Series D (L-Nutra), which suggests that large checks are still being written for companies with strong clinical or commercial stories.

Compared to Q1 2025, the longevity market funding landscape looks more diverse, with sovereign wealth funds like Mubadala entering alongside traditional venture capital, which is a meaningful shift in who is writing the biggest checks.

Average deal sizes in Q1 2026 appear to be skewing larger, driven by a handful of significant rounds, while smaller deals are still happening but getting less attention, which is typical of a market moving past the very early stage.

Which categories and business models are attracting capital in the longevity market?

These categories and business models of the longevity market are receiving important fundraising currently:

• Longevity preventive medicine companies with clinical assets, like Corsera Health, are attracting very large rounds because they combine a longevity story with a real clinical trial, which is exactly what investors want to see.
• Longevity nutrition and medical food companies, like L-Nutra, are raising significant capital from sovereign and institutional investors who see longevity nutrition as a global consumer category, not just a niche supplement play.
• AI-powered longevity platforms and enterprise health infrastructure are also picking up capital, as investors see these as the "picks and shovels" of the longevity market rather than a bet on one specific therapy.

The clearest pattern in Q1 2026 longevity market fundraising is that investors are rewarding companies that combine a credible scientific story with a clear path to revenue, whether through a drug trial, a subscription product, or an enterprise platform.

Who's writing the most checks in the longevity market?

These investors are being very active when it comes to fundraising in the longevity market:

• Mubadala is Abu Dhabi's sovereign wealth fund and backed L-Nutra with $36.5 million, which signals that government-linked capital from the Middle East is now a serious player in the longevity market.
• Government and quasi-public funders like ARPA-H are becoming increasingly active, funding seven healthspan research teams through the PROSPR program and bringing public money into longevity science in a way that was not happening a few years ago.

The most interesting shift in Q1 2026 is that the longevity market is no longer funded exclusively by private venture capital; sovereign wealth funds and government agencies are now actively writing checks, which will change the risk and return profile of the sector over time.

Any big acquisitions or IPOs in the last three months in the longevity market?

These are the big acquisitions that happened recently in the longevity market:

• Agentis Longevity acquired BioDesign in February 2026, adding Florida clinics to its portfolio and positioning itself as one of the first roll-up players in the longevity clinic space.

There were no major IPOs in the longevity market during Q1 2026, but the Agentis acquisition is a signal worth watching because clinic consolidation tends to accelerate once the first few buyers start making moves.

How are companies in the longevity market performing overall?

We are watching this market every day, because we need to constantly update our pitch deck. Here is a couple of things we have noticed.

Are there any standout success metrics or financial results in the longevity market?

Yes, Q1 2026 had some strong real-world performance data from longevity market companies:

• Fountain Life published real-world outcome data showing 51% of members with prediabetes returned to normal blood sugar in an average of 1.2 years, and 26% of members halted coronary plaque progression, based on more than 15 billion clinical data points from 8,000 members.

Fountain Life's data is one of the strongest real-world outcome datasets published by a commercial longevity company so far, and it raises the bar for what other longevity clinics will need to show investors and customers going forward.

Have there been any major partnerships in the longevity market?

Yes, several notable longevity market partnerships were announced in Q1 2026:

• UFC GYM and NexGen MD Scientific announced a partnership to open longevity clinics inside UFC GYM locations, starting in Torrance and Corona with plans to expand over the next 24 months.
• Human Longevity and the LEV Foundation announced a research collaboration focused on blood samples from centenarians and supercentenarians to identify biomarkers linked to exceptional longevity.
• The Healthspan Action Coalition united more than 300 organizations, making it the world's largest healthspan alliance and a growing policy force for the longevity market.

The UFC GYM partnership is the most strategically interesting one, because it could change how longevity medicine reaches mainstream consumers far more quickly than opening individual clinics one at a time.

Have there been any notable technology or infrastructure breakthroughs in the longevity market?

Yes, a couple of notable longevity market technology and infrastructure moves happened in Q1 2026:

• January AI launched its Enterprise Lifestyle Intelligence platform at CES 2026, shifting from a consumer app to an enterprise infrastructure layer that longevity companies, health systems, and institutional partners can plug into.
• Immorta Bio reported doubling mouse lifespan using a combination of its SenoVax senolytic therapy and personalized mesenchymal stem cells, which is one of the biggest preclinical results in the longevity space in recent memory.

January AI's infrastructure pivot is worth watching closely, because if longevity companies start using shared data layers rather than building everything themselves, it could dramatically speed up the whole longevity market.

Have any companies restructured or shifted pricing or business model in the longevity market?

Yes, a couple of longevity market companies made notable business model shifts in Q1 2026:

• Human Longevity launched a personal AI app to complement its clinic model, turning what was previously an episodic clinic visit into an always-on digital health service for members.
• ArentFox Schiff launched a dedicated longevity practice group, which is not a company restructuring but does reflect a broader shift in how seriously the legal and professional services world is now treating the longevity market as its own category.

The move by Human Longevity to add a digital layer is a sign that clinic-only models in the longevity market are starting to look incomplete, and that software will become a standard part of what longevity clinics offer.

Are there any other notable wins or successes in the longevity market?

Yes, a few more wins from the longevity market in Q1 2026 are worth highlighting:

• 20/20 BioLabs launched OneTest for Longevity, an AI-powered blood test built with IBM watsonx.ai that gives consumers a simple chronic disease risk score and personalized guidance.
• Withings launched Body Scan 2, a home longevity monitoring station that tracks more than 60 biomarkers and includes hypertension risk alerts and cardiac pumping assessment.

Both the 20/20 BioLabs and Withings launches point to the same trend: the longevity market is moving toward simpler, more consumer-friendly products that work at home, not just inside a premium clinic.

What is the overall sentiment in the longevity market right now?

Are there any notable recent opinion pieces, thought leadership about the longevity market?

No, we don't think there were any notable opinion pieces or thought leadership pieces specifically worth highlighting from Q1 2026 in the longevity market beyond what is already covered in the news and funding sections above.

Are there any interesting and recent market research reports about the longevity market?

Unfortunately, no specific new market research reports on the longevity market were published in Q1 2026 that stand out as must-reads beyond what we have already summarized in our own analysis above.

Have there been any regulatory changes, policy updates, or new compliance requirements in the longevity market?

Yes, there was one significant policy development in the longevity market in Q1 2026:

• ARPA-H formally announced funding for seven healthspan research teams through its PROSPR program on February 24, 2026, making it one of the first times the U.S. government has directly funded a longevity and healthspan research program at this scale.

The ARPA-H PROSPR announcement is not a regulation, but it is a clear signal that healthspan and longevity science is now on the U.S. government's radar as a public health priority, which could open the door to more non-dilutive funding opportunities for longevity market companies in the coming years.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.